Clinical Trial Results:
            A follow-on, multi-centre, open-label, clinical, phase 3 trial to investigate the persistence of serotype-specific antibodies at 40 months of age in children who have received either the 7-valent or the 13-valent pneumococcal conjugate vaccine at 2, 4 and 12 months of age and assessing the immunogenicity of a 13-valent pneumococcal conjugate vaccine booster dose given at 40 months of age
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2009-017498-39 | 
    Trial protocol  | 
        GB | 
    Global completion date  | 
        
                                    10 Dec 2012
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    01 Dec 2016
                             
         | 
    
    First version publication date  | 
        
                                    01 Dec 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                PCV13 Follow on Clinical Study Report | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.